COVID19: A message from the HLHS Consortium
We remain committed to conducting the vital work of bringing hope to CHD families through the development of regenerative medicine products. However, we respect that the situation is rapidly changing, and will only continue our work when and where it is safe to do so. We will continue to evaluate each cell delivery treatment on a case-by-case, site-by-site, and day-by-day basis.
Click here to read full message.
The Todd and Karen Wanek Family Program for HLHS at Mayo Clinic created the HLHS Consortium to improve access to clinical trials and allow researchers to pool scientific knowledge with top cardiovascular programs around the country. The consortium helps decrease the amount of time from research and discovery to the clinical application of innovative cell-based therapies.